Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4

被引:0
|
作者
Kristen C Hart
Scott C Robertson
Martha Y Kanemitsu
April N Meyer
John A Tynan
Daniel J Donoghue
机构
[1] University of California,Department of Chemistry and Biochemistry
来源
Oncogene | 2000年 / 19卷
关键词
FGFR; transformation; Stats; signal transduction;
D O I
暂无
中图分类号
学科分类号
摘要
The fibroblast growth factor receptor (FGFR) family members mediate a number of important cellular processes, and are mutated or overexpressed in several forms of human cancer. Mutation of Lys650→Glu in the activation loop of the FGFR3 kinase domain causes the lethal human skeletal disorder thanatophoric dysplasia type II (TDII) and is also found in patients with multiple myeloma, bladder and cervical carcinomas. This mutation leads to constitutive activation of FGFR3. To compare the signaling activity of FGFR family members, this activating mutation was generated in FGFR1, FGFR3, and FGFR4. We show that the kinase domains of FGFR1, FGFR3, and FGFR4 containing the activation loop mutation, when targeted to the plasma membrane by a myristylation signal, can transform NIH3T3 cells and induce neurite outgrowth in PC12 cells. Phosphorylation of Shp2, PLC-γ, and MAPK was also stimulated by all three ‘TDII-like’ FGFR derivatives. Additionally, activation of Stat1 and Stat3 was observed in cells expressing the activated FGFR derivatives. Finally, we demonstrate that FGFR1, FGFR3, and FGFR4 derivatives can stimulate PI-3 kinase activity. Our comparison of these activated receptor derivatives reveals a significant overlap in the panel of effector proteins used to mediate downstream signals. This also represents the first demonstration that activation of FGFR4, in addition to FGFR1 and FGFR3, can induce cellular transformation. Moreover, our results suggest that Stat activation by FGFRs is important in their ability to act as oncogenes.
引用
收藏
页码:3309 / 3320
页数:11
相关论文
共 50 条
  • [31] Differential regulation of endochondral bone growth and joint development by FGFR1 and FGFR3 tyrosine kinase domains
    Wang, O
    Green, RP
    Zhao, GY
    Ornitz, DM
    DEVELOPMENT, 2001, 128 (19): : 3867 - 3876
  • [32] Novel missense variants in FGFR1 and FGFR3 causes short stature in enrolled families from Pakistan
    Mustafa, Saima
    Akhtar, Zafreen
    Asif, Muhammad
    Amjad, Muhammad
    Ijaz, Maryam
    Latif, Muhammad
    Hassan, Mubashir
    Faisal, Muhammad
    Iqbal, Furhan
    META GENE, 2020, 26
  • [33] FGFR1/FGFR1 isoforms in prostate cancer progression to metastasis
    Labanca, E.
    Yang, J.
    Shepherd, P.
    Roberts, J.
    Starbuck, M.
    Broom, B.
    Iyer, M.
    Logothetis, C.
    Chinnaiyan, A.
    Navone, N.
    CLINICAL & EXPERIMENTAL METASTASIS, 2019, 36 (02) : 160 - 160
  • [34] Targetable FGFR3 Fusions and Novel FGFR3 Mutations in Glioma
    Schittenhelm, Jens
    Ziegler, Lukas
    Mittelbronn, Michel
    Capper, David
    Burghardt, Isabel
    Poso, Antti
    Biskup, Saskia
    Skardelly, Marko
    Tabatabal, Ghazaleh
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 33 - 33
  • [35] Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
    Yang, Chaofeng
    Jin, Chengliu
    Li, Xiaokun
    Wang, Fen
    McKeehan, Wallace L.
    Luo, Yongde
    PLOS ONE, 2012, 7 (03):
  • [36] Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcoma
    Charbonneau, Bridget
    Vogel, Rachel Isaksson
    Manivel, J. Carlos
    Rizzardi, Anthony
    Schmechel, Stephen C.
    Ognjanovic, Simona
    Subramanian, Subbaya
    Largaespada, David
    Weigel, Brenda
    HUMAN PATHOLOGY, 2013, 44 (09) : 1918 - 1926
  • [37] Fibroblast growth factor receptor 1 (FGFR1) is over-expressed in benign prostatic hyperplasia whereas FGFR2-IIIc and FGFR3 are not
    Boget, S
    Cereser, C
    Parvaz, P
    Leriche, A
    Revol, A
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2001, 145 (03) : 303 - 310
  • [38] FGFR1 and FGFR2 in fibrolamellar carcinoma
    Graham, Rondell P.
    Garcia, Joaquin J.
    Greipp, Patricia T.
    Fritcher, Emily G. Barr
    Kipp, Benjamin R.
    Torbenson, Michael S.
    HISTOPATHOLOGY, 2016, 68 (05) : 686 - 692
  • [39] Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors
    Li, Gary
    Krook, Melanie
    Roychowdhury, Sameek
    Avogadri, Francesca
    Ye, Yining
    Moran, Susan
    CANCER RESEARCH, 2019, 79 (13)
  • [40] FGFR3 is key
    Gemma K. Alderton
    Nature Reviews Cancer, 2009, 9 : 387 - 387